BioSpace

Summit snags $2B investment from AstraZeneca, clearing financial overhang

The all-stock deal gives Summit Therapeutics enough money to see through Phase 3 trials for the PD-1/VEGF bispecific ivonescimab—but keeps the asset fully in-house without giving up licensing rights.

Por BioSpace

1 minuto de lectura
Compartir
Summit snags $2B investment from AstraZeneca, clearing financial overhang
Summit snags $2B investment from AstraZeneca, clearing financial overhang

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Health Tech

Perspectivas relacionadas